Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation (scientific article published on 4 May 2011)

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Q29614889

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

Q33256792

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Q34437074

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

Q34714894

Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis

Q35098879

Molecular mechanisms of amyloidosis

Q35194628

Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation

Q43850604

Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.

Q46031457

Clinical and histological responses of renal amyloidosis to high-dose melphalan supported by autologous stem cell transplantation.

Q53517606

Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement.

Q53671959

P433

issue

P407

language of work or name

English

Q1860

P304

page(s)

2032-2036

P577

publication date

2011-05-04

P1433

published in

Nephrology Dialysis Transplantation

Q15710302

P1476

title

Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation

P478

volume

Reverse relations

cites work (P2860)

Q36965127	A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine
Q36392233	Al amyloidosis
Q37904673	Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.
Q26861037	Defining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasias
Q47428714	Dysproteinemias and Glomerular Disease
Q44907517	End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases.
Q38544723	Hematopoietic Cell and Renal Transplantation in Plasma Cell Dyscrasia Patients
Q38172295	Immunoglobulin light chain amyloidosis
Q26827340	Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment
Q34448455	Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment
Q38928383	Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment
Q41217389	Kidney Transplantation in Patients With Active Multiple Myeloma: Case Reports
Q38122674	Kidney disease and multiple myeloma
Q47561519	New concepts in the treatment and diagnosis of amyloidosis
Q51786246	Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.
Q40973226	Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement
Q30276115	Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance
Q38831139	Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias
Q38002959	Recurrence from primary and secondary glomerulopathy after renal transplant
Q98947237	Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management
Q44960748	Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis